Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
Hepatocellular carcinoma (HCC) is the second most common form of liver cancer occurring in pediatric patients. Many of these patients do not survive long-term, even if they initially respond to chemotherapy, because their disease has already metastasized, or spread to other organs. However, checkpoint inhibition—a type of immunotherapy that can unleash T cells against tumors—has been relatively effective in adults with HCC, and may offer a promising option for pediatric HCC patients, too.
To that end, Dr. O’Neill will soon start enrolling patients to a multi-institutional phase II clinical trial in which pediatric patients with relapsed or refractory HCC will be treated with checkpoint inhibition targeting the PD-1 pathway. In addition to evaluating the benefits of this approach for pediatric patients, Dr. O’Neill also aims to characterize the tumor immune environment for each patient’s tumor. This will potentially allow pairing of response rates with the immune characteristics of each tumor while identifying factors that might be prognostic and predictive of response, all with the goal of improving care for this patient population.
Dana-Farber Cancer Institute | Childhood Cancer, Liver Cancer | 2019
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).